Auch dank günstigen Abnehmspritzen: Sandoz will Umsatz mehr als verdoppeln
Der Basler Generikahersteller Sandoz setzt sich ehrgeizige Wachstumsziele. Ungelöst ist jedoch das Problem mit Trumps Zolldrohungen. Dem Unternehmen fehlt nach wie vor eine Produktionsstätte in den USA.
Basler generika-Hersteller Sandoz has ambitious growth targets, but faces challenges from Trump's potential trade tariffs. The company still lacks a U.S. production facility and remains one of the few generic drug manufacturers in the industry. Over the past two years, Sandoz has increased its revenue by 16 percent to 11.1 billion Swiss francs, with the adjusted EBITDA margin rising by 3.6 percentage points to 21.7 percent.
The firm aims to more than double its profitability by 2035, with an adjusted EBITDA margin above 30 percent. However, the company's future remains uncertain due to potential tariffs on generic drugs that the U.S. government intends to impose. Sandoz currently generates 55 percent of its revenue in Europe, but 25 percent comes from the U.S. The company has built three production facilities in Slovenia, including the new one, with hopes of expanding its U.S. operations.
Written by urgent.news from NZZ Wirtschaft's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Sandoz will Umsatz bis 2035 mehr als verdoppeln derstandard.at
